Cap

Zacks Small Cap Research – RVPH: Preliminary OLE Readout – Go Health Pro

by
Zacks Small Cap Research – RVPH: Preliminary OLE Readout – Go Health Pro

By John Vandermosten, CFA NASDAQ:RVPH READ THE FULL RVPH RESEARCH REPORT Open Label Extension Initial Readout Reviva Pharmaceutical Holdings, Inc. (NASDAQ:RVPH) reported preliminary results from its open label extension (OLE) portion of the Phase III RECOVER trial. Brilaroxazine showed a favorable long-term safety profile and improving efficacy over the one-year observation period. The schizophrenia candidate … Read more

Zacks Small Cap Research – MTVA: Compelling Data for DA-1241 in Phase 2a MASH Trial… – Go Health Pro

by
Zacks Small Cap Research – MTVA: Compelling Data for DA-1241 in Phase 2a MASH Trial… – Go Health Pro

By David Bautz, PhD NASDAQ:MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Compelling Results for DA-1241 in Phase 2a MASH Trial On December 18, 2024, MetaVia Inc. (NASDAQ:MTVA) announced positive topline results from the 16-week Phase 2a clinical trial of DA-1241 in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH). The trial had two parts: … Read more

Zacks Small Cap Research – MIRA Makes Major Strides – Go Health Pro

by

By Brad Sorensen, CFA NASDAQ:MIRA READ THE FULL MIRA RESEARCH REPORT MIRA Pharmaceuticals (NASDAQ:MIRA) is a preclinical-stage pharmaceutical company that is about to be a clinical-stage company focused on the development and commercialization of a new molecular synthetic cannabinoid analog for the treatment of adult patients with neuropathic pain as well as anxiety and cognitive … Read more

Zacks Small Cap Research – SNGX: Phase 3 FLASH2 Trial of HyBryte in CTCL Underway… – Go Health Pro

by
Zacks Small Cap Research – SNGX: Phase 3 FLASH2 Trial of HyBryte in CTCL Underway… – Go Health Pro

By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Phase 3 FLASH2 Trial of HyBryte in CTCL is Underway On December 16, 2024, Soligenix, Inc. (NASDAQ:SNGX) announced that patient enrollment has opened up for the confirmatory Phase 3 FLASH2 (Fluorescent Light Activated Synthetic Hypericin 2) trial of HyBryte in patients with … Read more

Zacks Small Cap Research – CTSO: CytoSorbents Announces Rights Offering Which has the Potential to Substantially Increase Available Liquidity – Go Health Pro

by

By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT On December 9, 2024, CytoSorbents (NASDAQ:CTSO) announced a shareholder friendly anticipated Rights Offering which is expected to substantially increase its liquidity position. Investors who own or have bought CTSO stock by the close of trading on Friday, December 13, 2024 will be considered stockholders … Read more

x